BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 27004693)

  • 1. Histopathological Outcomes after Irreversible Electroporation for Prostate Cancer: Results of an Ablate and Resect Study.
    van den Bos W; Jurhill RR; de Bruin DM; Savci-Heijink CD; Postema AW; Wagstaff PG; Muller BG; Varkarakis IM; Skolarikos A; Zondervan PJ; Laguna Pes MP; de Reijke TM; de la Rosette JJ
    J Urol; 2016 Aug; 196(2):552-9. PubMed ID: 27004693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The correlation between the electrode configuration and histopathology of irreversible electroporation ablations in prostate cancer patients.
    van den Bos W; de Bruin DM; Jurhill RR; Savci-Heijink CD; Muller BG; Varkarakis IM; Skolarikos A; Zondervan PJ; Laguna-Pes MP; Wijkstra H; de Reijke TM; de la Rosette JJ
    World J Urol; 2016 May; 34(5):657-64. PubMed ID: 26296371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of irreversible electroporation for the ablation of prostate cancer: a multicentre prospective human in vivo pilot study protocol.
    van den Bos W; de Bruin DM; Muller BG; Varkarakis IM; Karagiannis AA; Zondervan PJ; Laguna Pes MP; Veelo DP; Savci Heijink CD; Engelbrecht MRW; Wijkstra H; de Reijke TM; de la Rosette JJMCH
    BMJ Open; 2014 Oct; 4(10):e006382. PubMed ID: 25354827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot Study to Assess Safety and Clinical Outcomes of Irreversible Electroporation for Partial Gland Ablation in Men with Prostate Cancer.
    Murray KS; Ehdaie B; Musser J; Mashni J; Srimathveeravalli G; Durack JC; Solomon SB; Coleman JA
    J Urol; 2016 Sep; 196(3):883-90. PubMed ID: 27113966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial Assessment of the Efficacy of Irreversible Electroporation in the Focal Treatment of Localized Renal Cell Carcinoma With Delayed-interval Kidney Tumor Resection (Irreversible Electroporation of Kidney Tumors Before Partial Nephrectomy [IRENE] Trial-An Ablate-and-Resect Pilot Study).
    Wendler JJ; Pech M; Fischbach F; Jürgens J; Friebe B; Baumunk D; Porsch M; Blaschke S; Schindele D; Siedentopf S; Ricke J; Schostak M; Köllermann J; Liehr UB
    Urology; 2018 Apr; 114():224-232. PubMed ID: 29305201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percutaneous irreversible electroporation (IRE) of prostate cancer: Contrast-enhanced ultrasound (CEUS) findings during follow up.
    Beyer LP; Pregler B; Nießen C; Michalik K; Haimerl M; Stroszczynski C; Jung EM; Wiggermann P
    Clin Hemorheol Microcirc; 2016; 64(3):501-506. PubMed ID: 27935553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focal vs extended ablation in localized prostate cancer with irreversible electroporation; a multi-center randomized controlled trial.
    Scheltema MJ; van den Bos W; de Bruin DM; Wijkstra H; Laguna MP; de Reijke TM; de la Rosette JJ
    BMC Cancer; 2016 May; 16():299. PubMed ID: 27150293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI and contrast-enhanced ultrasound imaging for evaluation of focal irreversible electroporation treatment: results from a phase I-II study in patients undergoing IRE followed by radical prostatectomy.
    van den Bos W; de Bruin DM; van Randen A; Engelbrecht MR; Postema AW; Muller BG; Varkarakis IM; Skolarikos A; Savci-Heijink CD; Jurhill RR; Zondervan PJ; Laguna Pes MP; Wijkstra H; de Reijke TM; de la Rosette JJ
    Eur Radiol; 2016 Jul; 26(7):2252-60. PubMed ID: 26449559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Step-by-Step Technique for Irreversible Electroporation of Focal Prostate Cancer: An Instructional Video Guide.
    Ting F; Van Leeuwen PJ; Stricker PD
    J Vasc Interv Radiol; 2016 Apr; 27(4):568. PubMed ID: 27013005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ablation of colorectal liver metastases by irreversible electroporation: results of the COLDFIRE-I ablate-and-resect study.
    Scheffer HJ; Nielsen K; van Tilborg AA; Vieveen JM; Bouwman RA; Kazemier G; Niessen HW; Meijer S; van Kuijk C; van den Tol MP; Meijerink MR
    Eur Radiol; 2014 Oct; 24(10):2467-75. PubMed ID: 24939670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Focal ablation of apical prostate cancer lesions with irreversible electroporation (IRE).
    Blazevski A; Amin A; Scheltema MJ; Balakrishnan A; Haynes AM; Barreto D; Cusick T; Thompson J; Stricker PD
    World J Urol; 2021 Apr; 39(4):1107-1114. PubMed ID: 32488359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why we should not routinely apply irreversible electroporation as an alternative curative treatment modality for localized prostate cancer at this stage.
    Wendler JJ; Ganzer R; Hadaschik B; Blana A; Henkel T; Köhrmann KU; Machtens S; Roosen A; Salomon G; Sentker L; Witzsch U; Schlemmer HP; Baumunk D; Köllermann J; Schostak M; Liehr UB
    World J Urol; 2017 Jan; 35(1):11-20. PubMed ID: 27147512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First Human Trial of High-Frequency Irreversible Electroporation Therapy for Prostate Cancer.
    Dong S; Wang H; Zhao Y; Sun Y; Yao C
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818789692. PubMed ID: 30045668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irreversible electroporation for the treatment of localized prostate cancer: a summary of imaging findings and treatment feedback.
    Scheltema MJ; Postema AW; de Bruin DM; Buijs M; Engelbrecht MR; Laguna MP; Wijkstra H; de Reijke TM; de la Rosette JJMCH
    Diagn Interv Radiol; 2017; 23(5):365-370. PubMed ID: 28830850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time-Dependent Impact of Irreversible Electroporation on Pathology and Ablation Size in the Porcine Liver: A 24-Hour Experimental Study.
    Vogel JA; van Veldhuisen E; Alles LK; Busch OR; Dijk F; van Gulik TM; Huijzer GM; Besselink MG; van Lienden KP; Verheij J
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819876899. PubMed ID: 31533537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled trial on focal therapy for localized prostate carcinoma: hemiablation versus complete ablation with irreversible electroporation.
    van den Bos W; Muller BG; de la Rosette JJ
    J Endourol; 2013 Mar; 27(3):262-4. PubMed ID: 23469828
    [No Abstract]   [Full Text] [Related]  

  • 17. Irreversible electroporation: implications for prostate ablation.
    Onik G; Mikus P; Rubinsky B
    Technol Cancer Res Treat; 2007 Aug; 6(4):295-300. PubMed ID: 17668936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Focal vs Extended Irreversible Electroporation for the Ablation of Localized Low- or Intermediate-Risk Prostate Cancer on Early Oncological Control: A Randomized Clinical Trial.
    Zhang K; Teoh J; Laguna P; Dominguez-Escrig J; Barret E; Ramon-Borja JC; Muir G; Bohr J; de Reijke TM; Pelechano Gómez P; Ng CF; Sanchez-Salas R; de la Rosette J
    JAMA Surg; 2023 Apr; 158(4):343-349. PubMed ID: 36723911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Irreversible Electroporation Can Effectively Ablate Hepatocellular Carcinoma to Complete Pathologic Necrosis.
    Cheng RG; Bhattacharya R; Yeh MM; Padia SA
    J Vasc Interv Radiol; 2015 Aug; 26(8):1184-8. PubMed ID: 26119204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Irreversible electroporation (IRE) : A minimally invasive therapeutic option in prostate cancer].
    Wiggermann P; Brünn K; Bäumler W
    Radiologe; 2017 Aug; 57(8):637-640. PubMed ID: 28477079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.